Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.78 Analyst target: $4.00 Upside: 416.13%
Dermata Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for dermatological conditions, particularly through its lead candidate, DMT310. Utilizing a proprietary delivery system, DMT310 seeks to enhance the efficacy of existing acne treatments while addressing significant unmet needs within the dermatology space. With a robust pipeline and a commitment to pioneering dermatological solutions, Dermata Therapeutics is positioned to make a meaningful impact on skin health and improve patient outcomes. As the company advances in its clinical trials, it holds the potential to become a disruptive player in the treatment of skin disorders.
See the full interactive analysis & chart →Informational only — not investment advice.